BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee CY. A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment. Front Endocrinol (Lausanne) 2021;12:748477. [PMID: 34616367 DOI: 10.3389/fendo.2021.748477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C, Gu M. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13:935823. [DOI: 10.3389/fphar.2022.935823] [Reference Citation Analysis]
2 Ibnat N, Zaman R, Uddin MB, Chowdhury E, Lee CY. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World J Diabetes 2022; 13(8): 613-621 [DOI: 10.4239/wjd.v13.i8.613] [Reference Citation Analysis]